Annual CFF
$31.50 M
+$27.61 M+709.87%
31 December 2023
Summary:
Galera Therapeutics annual cash flow from financing activities is currently $31.50 million, with the most recent change of +$27.61 million (+709.87%) on 31 December 2023. During the last 3 years, it has risen by +$10.99 million (+53.59%). GRTX annual CFF is now -64.94% below its all-time high of $89.84 million, reached on 31 December 2018.GRTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
$0.000.00%
30 June 2024
Summary:
Galera Therapeutics quarterly cash flow from financing activities is currently $0.00, unchanged on 30 June 2024. Over the past year, it has dropped by -$2.13 million (-100.00%). GRTX quarterly CFF is now -100.00% below its all-time high of $59.70 million, reached on 31 December 2019.GRTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$1.90 M
-$1.81 M-48.79%
30 June 2024
Summary:
Galera Therapeutics TTM cash flow from financing activities is currently $1.90 million, with the most recent change of -$1.81 million (-48.79%) on 30 June 2024. Over the past year, it has dropped by -$32.53 million (-94.48%). GRTX TTM CFF is now -98.06% below its all-time high of $98.04 million, reached on 31 March 2020.GRTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GRTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +709.9% | -100.0% | -94.5% |
| 3 y3 years | +53.6% | -100.0% | -97.2% |
| 5 y5 years | -64.9% | +100.0% | -89.6% |
GRTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -52.8% | +709.9% | -100.0% | +100.0% | -97.2% | +57.3% |
| 5 y | 5 years | -64.9% | +709.9% | -100.0% | +100.0% | -98.1% | +159.8% |
| alltime | all time | -64.9% | -100.0% | +100.0% | -98.1% |
Galera Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | $0.00(0.0%) | $1.90 M(-48.8%) |
| Mar 2024 | - | $0.00(-100.0%) | $3.71 M(-88.2%) |
| Dec 2023 | $31.50 M(+709.9%) | -$232.00 K(-110.9%) | $31.50 M(-8.5%) |
| Sept 2023 | - | $2.13 M(+17.8%) | $34.43 M(+6.6%) |
| June 2023 | - | $1.81 M(-93.5%) | $32.31 M(+5.9%) |
| Mar 2023 | - | $27.78 M(+928.2%) | $30.50 M(+684.2%) |
| Dec 2022 | $3.89 M(-94.2%) | $2.70 M(>+9900.0%) | $3.89 M(+221.7%) |
| Sept 2022 | - | $10.00 K(+400.0%) | $1.21 M(-97.1%) |
| June 2022 | - | $2000.00(-99.8%) | $41.81 M(-38.2%) |
| Mar 2022 | - | $1.18 M(+5240.9%) | $67.65 M(+1.4%) |
| Dec 2021 | $66.71 M | $22.00 K(-99.9%) | $66.71 M(-0.3%) |
| Sept 2021 | - | $40.61 M(+57.2%) | $66.92 M(+152.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | $25.84 M(>+9900.0%) | $26.53 M(+3524.2%) |
| Mar 2021 | - | $235.00 K(+1.3%) | $732.00 K(-96.4%) |
| Dec 2020 | $20.51 M(-73.7%) | $232.00 K(+3.6%) | $20.51 M(-74.4%) |
| Sept 2020 | - | $224.00 K(+446.3%) | $79.98 M(+0.7%) |
| June 2020 | - | $41.00 K(-99.8%) | $79.41 M(-19.0%) |
| Mar 2020 | - | $20.01 M(-66.5%) | $98.04 M(+25.6%) |
| Dec 2019 | $78.03 M(-13.1%) | $59.70 M(<-9900.0%) | $78.03 M(+325.7%) |
| Sept 2019 | - | -$345.00 K(-101.8%) | $18.33 M(-1.8%) |
| June 2019 | - | $18.67 M(>+9900.0%) | $18.67 M(>+9900.0%) |
| Mar 2019 | - | $0.00 | $0.00 |
| Dec 2018 | $89.84 M(>+9900.0%) | - | - |
| Dec 2017 | $0.00 | - | - |
FAQ
- What is Galera Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Galera Therapeutics?
- What is Galera Therapeutics annual CFF year-on-year change?
- What is Galera Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Galera Therapeutics?
- What is Galera Therapeutics quarterly CFF year-on-year change?
- What is Galera Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Galera Therapeutics?
- What is Galera Therapeutics TTM CFF year-on-year change?
What is Galera Therapeutics annual cash flow from financing activities?
The current annual CFF of GRTX is $31.50 M
What is the all time high annual CFF for Galera Therapeutics?
Galera Therapeutics all-time high annual cash flow from financing activities is $89.84 M
What is Galera Therapeutics annual CFF year-on-year change?
Over the past year, GRTX annual cash flow from financing activities has changed by +$27.61 M (+709.87%)
What is Galera Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of GRTX is $0.00
What is the all time high quarterly CFF for Galera Therapeutics?
Galera Therapeutics all-time high quarterly cash flow from financing activities is $59.70 M
What is Galera Therapeutics quarterly CFF year-on-year change?
Over the past year, GRTX quarterly cash flow from financing activities has changed by -$2.13 M (-100.00%)
What is Galera Therapeutics TTM cash flow from financing activities?
The current TTM CFF of GRTX is $1.90 M
What is the all time high TTM CFF for Galera Therapeutics?
Galera Therapeutics all-time high TTM cash flow from financing activities is $98.04 M
What is Galera Therapeutics TTM CFF year-on-year change?
Over the past year, GRTX TTM cash flow from financing activities has changed by -$32.53 M (-94.48%)